You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(02142.HK):HBM1007臨牀試驗啟動獲美國FDA新藥研究許可
格隆匯 01-19 06:34

格隆匯1月19日丨和鉑醫藥-B(02142.HK)發佈公吿,公司已獲美國食品及藥物監督管理局(“FDA”)的新藥研究申請許可(“IND”)在美國啟動單克隆抗體HBM1007(一款由 Harbour Mice®平台產生的靶向CD73的全人源抗體)的臨牀試驗。

HBM1007是一款由集團的H2L2平台產生的對抗CD73的全人源單抗。HBM1007為一種在基質細胞及腫瘤表達的可將胞外腺苷單磷酸(AMP)轉化為腺苷的胞外酶。憑藉識別CD73的獨特表位,HBM1007通過雙重作用機制工作:一是可阻止細胞膜及可溶性CD73的酶活性,而不受AMP濃度的影響,表明其在腫瘤微環境(TME)中具有持續活性;二是減少CD73在細胞膜表面的表達,因此,CD73酶依賴及非酶依賴的功能活性均顯著降低。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account